LinkedIn Profile

Access Cara Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:cara 67344 Mar 24th, 2024 12:00AM Cara Therapeutics 5.7K 85.00 Open Mar 24th, 2024 12:03AM Mar 24th, 2024 12:03AM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 23rd, 2024 12:00AM Cara Therapeutics 5.7K 85.00 Open Mar 22nd, 2024 11:10PM Mar 23rd, 2024 06:29PM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 22nd, 2024 12:00AM Cara Therapeutics 5.7K 85.00 Open Mar 21st, 2024 11:10PM Mar 22nd, 2024 06:18PM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 21st, 2024 12:00AM Cara Therapeutics 5.7K 85.00 Open Mar 20th, 2024 11:16PM Mar 21st, 2024 05:01PM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 20th, 2024 12:00AM Cara Therapeutics 5.7K 85.00 Open Mar 19th, 2024 11:31PM Mar 20th, 2024 07:01PM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 19th, 2024 12:00AM Cara Therapeutics 5.7K 85.00 Open Mar 18th, 2024 10:57PM Mar 19th, 2024 05:34PM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 18th, 2024 12:00AM Cara Therapeutics 5.7K 85.00 Open Mar 17th, 2024 11:19PM Mar 18th, 2024 06:45PM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 17th, 2024 12:00AM Cara Therapeutics 5.7K 86.00 Open Mar 17th, 2024 12:03AM Mar 17th, 2024 12:03AM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 16th, 2024 12:00AM Cara Therapeutics 5.7K 87.00 Open Mar 15th, 2024 10:46PM Mar 16th, 2024 06:33PM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:cara 67344 Mar 15th, 2024 12:00AM Cara Therapeutics 5.7K 87.00 Open Mar 14th, 2024 11:48PM Mar 15th, 2024 08:20AM Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. Open Open 4 Stamford Plaza Stamford Connecticut US 06902 Cara Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.